SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Zydus Cadila receives EIR for Moraiya manufacturing facility

21 Jun 2017 Evaluate

Zydus Cadila’s formulations manufacturing facility at Moraiya, Ahmedabad has received an Establishment Inspection Report (EIR) from the United States Food & Drug Administration (USFDA) signifying the successful closure of the audit. The Moraiya manufacturing plant had completed the USFDA audit from February 6th to 15th 2017 with Zero 483 observations. Post the audit, the plant has received several product approvals, including the final approval to market Mesalamine Delayed- Release Tablets USP, 1.2 g in the US.

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.

Zydus Lifesciences Share Price

941.45 -1.10 (-0.12%)
20-Apr-2026 11:29 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1673.50
Dr. Reddys Lab 1237.75
Cipla 1238.15
Zydus Lifesciences 941.45
Lupin 2330.75
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×